A White Paper—Consensus and Recommendations of a Global Harmonization Team on Assessing the Impact of Immunogenicity on Pharmacokinetic Measurements
暂无分享,去创建一个
K. Sonehara | H. Myler | B. Gorovits | R. Pillutla | J. Sailstad | J. Wustner | A. Clements-Egan | M. K. Rose | L. Amaravadi | M. Putman | L. Tang | S. Pursuhothama
[1] P. Vicini,et al. A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics , 2013, The AAPS Journal.
[2] V. Jawa,et al. Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment , 2013, The AAPS Journal.
[3] Jihong Yang,et al. Theoretical Considerations and Practical Approaches to Address the Effect of Anti-drug Antibody (ADA) on Quantification of Biotherapeutics in Circulation , 2013, The AAPS Journal.
[4] Surinder Kaur,et al. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. , 2013, Bioanalysis.
[5] Iain Gardner,et al. Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies , 2013, Clinical Pharmacokinetics.
[6] J. Pérez-Ruixo,et al. Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours , 2012, Clinical Pharmacokinetics.
[7] D. Mould,et al. Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.
[8] Yaoli Song,et al. Effects of PEGylation and Immune Complex Formation on the Pharmacokinetics and Biodistribution of Recombinant Interleukin 10 in Mice , 2012, Drug Metabolism and Disposition.
[9] N. Dontha,et al. Ligand Binding Assays in the 21st Century Laboratory: Platforms , 2012, The AAPS Journal.
[10] J. P. Perez Ruixo,et al. The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics , 2012, The AAPS Journal.
[11] J. Pérez-Ruixo,et al. Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis , 2011, Clinical pharmacokinetics.
[12] J. Pérez-Ruixo,et al. Immunogenicity of panitumumab in combination chemotherapy clinical trials , 2011, BMC clinical pharmacology.
[13] J. Sailstad,et al. Understanding and mitigating impact of immunogenicity on pharmacokinetic assays. , 2011, Bioanalysis.
[14] E. Martı́n-Mola,et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. , 2011, Rheumatology.
[15] R. Faggioni,et al. PK-PD modeling of protein drugs: implications in assay development. , 2011, Bioanalysis.
[16] L. Howes,et al. Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer , 2011, BMC clinical pharmacology.
[17] Heather Myler,et al. Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.
[18] Guodong Chen,et al. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies , 2011, Analytical and Bioanalytical Chemistry.
[19] L. Roskos,et al. Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab , 2010, Clinical pharmacokinetics.
[20] Jean W. Lee,et al. Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand. , 2010, Journal of pharmaceutical and biomedical analysis.
[21] L. Wilkins. Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study , 2010, Neurology.
[22] B. Dijkmans,et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis , 2010, Annals of the rheumatic diseases.
[23] P. Rutgeerts,et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.
[24] Yow-Ming C Wang,et al. Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors , 2009, Journal of clinical pharmacology.
[25] P. Bonate,et al. Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme® , 2009, Journal of Pharmacokinetics and Pharmacodynamics.
[26] B. Bénichou,et al. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. , 2009, Molecular genetics and metabolism.
[27] Viswanath Devanarayan,et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.
[28] Hendrik Neubert,et al. Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. , 2008, Analytical chemistry.
[29] Olivier Heudi,et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. , 2008, Analytical chemistry.
[30] Viswanath Devanarayan,et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. , 2008, Journal of immunological methods.
[31] Eric Woolf,et al. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples , 2007, The AAPS Journal.
[32] Vinod P. Shah,et al. Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007, The AAPS Journal.
[33] Yong-Sung Kim,et al. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. , 2007, Journal of molecular biology.
[34] Deqin Sun,et al. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. , 2007, Regulatory toxicology and pharmacology : RTP.
[35] Jana S Chain,et al. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. , 2007, Journal of immunological methods.
[36] Arunan Kaliyaperumal,et al. Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab , 2007, The Journal of Immunology.
[37] K. Bendtzen,et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.
[38] Eugen Koren,et al. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. , 2005, Journal of immunological methods.
[39] Binodh DeSilva,et al. Bioanalytical Method Validation for Macromolecules in Support of Pharmacokinetic Studies , 2005, Pharmaceutical Research.
[40] L. Kappos,et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. , 2005 .
[41] C. Wagner,et al. Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys , 2005, Journal of Pharmacology and Experimental Therapeutics.
[42] P. Anderson. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. , 2005, Seminars in arthritis and rheumatism.
[43] George Scott,et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.
[44] Binodh DeSilva,et al. Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.
[45] Thomas Layloff,et al. Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies , 1992, Pharmaceutical Research.
[46] M. Borggrefe,et al. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies. , 2002, Seminars in thrombosis and hemostasis.
[47] K. Roux,et al. Idiotypic–anti‐idiotypic complexes and their in vivo metabolism , 2002, Cancer.
[48] M. Tomonaga,et al. Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody , 2001, International journal of hematology.
[49] P. Lachmann,et al. Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. , 1997, European journal of immunology.
[50] P. Lachmann,et al. A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes , 1995, Clinical and experimental immunology.